Featured

Status

Health Topics

Any Category
Diseases
Hemic and Lymphatic Diseases
Hematologic Diseases
Clear Filters

Search Clinical Trials

19 Results
Completed
Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR
To participate in this study, patients will need to have given informed consent to have a bone marrow transplant. Before receiving the tetanus vaccine, we would like to test the …
Baylor Role: Collaborator
Terminated
T-Reg Cell Kinetics, Stem Cell Transplant, REGALE
To participate in this transplant, the patient will need to have a central line. Before the transplant we will test the blood for viruses which can cause problems after the …
Baylor Role: Lead Sponsor
Completed
Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD
Participation in this protocol will last about 1 year. To participate in this study, the patient will need to have undergone a stem cell transplant. Before the treatment starts, investigators …
Baylor Role: Lead Sponsor
Terminated
Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)
Allogeneic stem cell transplantation with high-dose chemotherapy affords a better chance of cure of malignant and non-malignant hematological diseases compared to autologous transplantation, because of the lack of stem cell …
Baylor Role: Lead Sponsor
Terminated
Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT
Patients will have received a haplo-identical stem cell transplant on our on-going study "CD45 (YTH-24 and YTH-54) and CD52 (Campath 1H) Monoclonal Antibody Conditioning Regimen for Allogeneic Donor Stem Cell …
Baylor Role: Lead Sponsor
Terminated
Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia
Before patients receive any treatments, they will have the following: - Complete history and physical exam - Dental consultation - Bone marrow aspirate - Blood tests - Urinanalysis - Tests …
Baylor Role: Lead Sponsor
Terminated
Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML
We expect that the patient's participation in this study will last approximately 18 months to 2 years. Before treatment begins, they will be evaluated to confirm they meet the requirements …
Baylor Role: Lead Sponsor
Terminated
Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia
If clinically feasible (no aplasia, no active malignancy), the recipients marrow will be harvested and cryopreserved as a back up for use if non-engraftment/rejection is followed by failure to undergo …
Baylor Role: Lead Sponsor
Completed
T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
To participate in this study, the subject will need to have a central line (a thin plastic catheter or tube that is placed during surgery into one of the large …
Baylor Role: Lead Sponsor